Background and Objectives

This trial targets patients with hormone receptor-positive, HER2-negative stage 2-3 breast cancer who exhibit MammaPrint High 2 Risk results. The goal is to reduce the risk of recurrence by combining durvalumab, an immune checkpoint inhibitor, with standard chemotherapy.

Differentiation in Treatment Mechanism

Durvalumab blocks PD-L1 on tumor cells, restoring T-cell activity. This represents an immune-based approach, distinct from traditional chemotherapy, which induces cell death. The combination of these two treatments is expected to create a synergistic effect by simultaneously inducing cancer cell death and activating the immune system.

Key Aspects of the Clinical Design

A Phase 3, randomized, controlled trial comparing the durvalumab combination arm with the chemotherapy-alone arm. The primary endpoint is disease-free survival (DFS), with the target population being patients in the MP2 risk group. Enrollment is currently underway, with a start date of November 27, 2023, and the completion date yet to be specified.

Market and Patient Impact

Hormone receptor-positive, HER2-negative breast cancer accounts for approximately 70% of all breast cancers, but there are limited additional treatment options for high-risk subtypes. If successful, the combination of immune checkpoint inhibitors and chemotherapy could establish a new standard of care. This could impact long-term survival rates and alter treatment cost structures for patients.